Brief: Braxia Scientific To Commence Canada's First Multiple-Dose Psilocybin Trial For Treatment Resistant Depression
27/08/2021 12:04
Aug 27 (Reuters) - Braxia Scientific Corp BRAX.CD :
* BRAXIA SCIENTIFIC TO COMMENCE LANDMARK CLINICAL TRIAL TO
CONDUCT
CANADA'S FIRST MULTIPLE-DOSE PSILOCYBIN CLINICAL TRIAL FOR
TREATMENT RESISTANT DEPRESSION
Source text for Eikon: ID:nCNWD2fY1a
Further company coverage: BRAX.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Braxia Scientific
See all newsBrief: Braxia Scientific Reports Q3 2022 Financial Results
Brief: Braxia Scientific CEO Roger Mcintyre To Join Advisory Board Of At-Home Telemedicine Platform KetaMD
Brief: Braxia Scientific To Commence Canada's First Multiple-Dose Psilocybin Trial For Treatment Resistant Depression
Brief: Braxia Scientific Launches Psilocybin-Assisted Clinical Therapy Training Program
Brief: Braxia Scientific Awarded Government Of Canada Funding To Complete First Of Its Kind Ketamine Clinical Trial For Bipolar Depression